Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Agenus Inc

Current price
6.3 USD -0.16 USD (-2.48%)
Last closed 6.5 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 170 709 888 USD
Yield for 12 month +275.00 %
21.11.2021 - 28.11.2021

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

5.5 USD

P/E ratio

Dividend Yield

Current Year

+156 314 000 USD

Last Year

+98 024 000 USD

Current Quarter

+83 801 000 USD

Last Quarter

+24 314 000 USD

Current Year

+139 615 000 USD

Last Year

-99 235 000 USD

Current Quarter

+78 340 000 USD

Last Quarter

-27 432 000 USD

Key Figures AGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -146 516 992 USD
Operating Margin TTM -5.2 %
PE Ratio
Return On Assets TTM -27.51 %
PEG Ratio
Return On Equity TTM -1278.83 %
Wall Street Target Price 5.5 USD
Revenue TTM 156 314 000 USD
Book Value -8.13 USD
Revenue Per Share TTM 8.74 USD
Dividend Share
Quarterly Revenue Growth YOY 195.2 %
Dividend Yield
Gross Profit TTM 82 609 000 USD
Earnings Share -13.8 USD
Diluted Eps TTM -13.8 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -157.22 %

Dividend Analytics AGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 12.04.2024
Dividend Date

Stock Valuation AGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.1043
Price Sales TTM 1.0921
Enterprise Value EBITDA -1.1829
Price Book MRQ 218.6149

Financials AGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AGEN

For 52 weeks

6.43 USD 42.6 USD
50 Day MA 12.49 USD
Shares Short Prior Month 45 745 667
200 Day MA 18.6 USD
Short Ratio 5.97
Shares Short 47 723 908
Short Percent 11.48 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics